These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11399937)

  • 21. [Efficacy of topical 2% cyclosporine A as a steroid-sparing agent in steroid-dependent vernal keratoconjunctivitis].
    Doan S; Gabison E; Abitbol O; Gatinel D; Chast F; Hoang-Xuan T
    J Fr Ophtalmol; 2007 Sep; 30(7):697-701. PubMed ID: 17878822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corneal Microstructural Changes by Confocal Microscopy in Vernal Keratoconjunctivitis Patients Treated with Topical Cyclosporine.
    Modugno RL; Scalora T; Bonaldo A; Lazzarini D; Leonardi A
    Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1599-1605. PubMed ID: 32275180
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of severe vernal keratoconjunctivitis with 1% topical cyclosporine in an Italian cohort of 197 children.
    Tesse R; Spadavecchia L; Fanelli P; Rizzo G; Procoli U; Brunetti L; Cardinale F; Miniello VL; Bellizzi M; Armenio L
    Pediatr Allergy Immunol; 2010 Mar; 21(2 Pt 1):330-5. PubMed ID: 19840298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions.
    Fukushima A; Yamaguchi T; Ishida W; Fukata K; Liu FT; Ueno H
    Clin Exp Ophthalmol; 2006; 34(4):347-53. PubMed ID: 16764655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children.
    Labcharoenwongs P; Jirapongsananuruk O; Visitsunthorn N; Kosrirukvongs P; Saengin P; Vichyanond P
    Asian Pac J Allergy Immunol; 2012 Sep; 30(3):177-84. PubMed ID: 23156846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model.
    Moore CP; McHugh JB; Thorne JG; Phillips TE
    Invest Ophthalmol Vis Sci; 2001 Mar; 42(3):653-9. PubMed ID: 11222523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topical cyclosporin A in the management of vernal keratoconjunctivitis.
    Gupta V; Sahu PK
    Eye (Lond); 2001 Feb; 15(Pt 1):39-41. PubMed ID: 11318292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eyelash length in children with vernal keratoconjunctivitis: effect of treatment with cyclosporine eye drops.
    Pucci N; Massai C; Bernardini R; Caputo R; Mori F; De Libero C; Novembre E; De Martino M; Vierucci A
    Int J Immunopathol Pharmacol; 2007; 20(3):595-9. PubMed ID: 17880772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory effects of cyclosporine a eye drops on symptoms in late phase and delayed-type reactions in allergic conjunctivitis models.
    Shii D; Nakagawa S; Yoshimi M; Katsuta O; Oda T; Nakamura M
    Biol Pharm Bull; 2010; 33(8):1314-8. PubMed ID: 20686224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applications of topical immunomodulators enhance clinical signs of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC): a meta-analysis.
    Erdinest N; Noyman DBE; London N; Lavy I; Levinger N; Landau D; Solomon A; Morad Y; Naroo SA
    Int Ophthalmol; 2024 Mar; 44(1):157. PubMed ID: 38522059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of 2% Rebamipide Suspension for Vernal Keratoconjunctivitis: A Clinical Comparison with Topical Immune Modulators Cyclosporine and Tacrolimus.
    Malhotra C; Singh H; Jain AK; Gupta A; Ram J
    Ocul Immunol Inflamm; 2022 Jul; 30(5):1083-1091. PubMed ID: 33764241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vernal shield ulcers treated with frequently installed topical cyclosporine 0.05% eyedrops.
    Westland T; Patryn EK; Nieuwendaal CP; van der Meulen IJE; Mourits MP; Lapid-Gortzak R
    Int Ophthalmol; 2018 Feb; 38(1):363-368. PubMed ID: 28120172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-mobility group box-1 (HMGB-1) and serum soluble receptor for advanced glycation end products (sRAGE) in children affected by vernal keratoconjunctivitis.
    Zicari AM; Zicari A; Nebbioso M; Mari E; Celani C; Lollobrigida V; Cesoni Marcelli A; Occasi F; Duse M
    Pediatr Allergy Immunol; 2014 Feb; 25(1):57-63. PubMed ID: 24236762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Topical Cyclosporine 0.05% the Treatment of Vernal Keratoconjunctivitis.
    Subedi K; Sharma B; Shrestha S
    Nepal J Ophthalmol; 2020 Jan; 12(23):39-47. PubMed ID: 32799238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes.
    Kunert KS; Tisdale AS; Stern ME; Smith JA; Gipson IK
    Arch Ophthalmol; 2000 Nov; 118(11):1489-96. PubMed ID: 11074805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis.
    Pucci N; Novembre E; Cianferoni A; Lombardi E; Bernardini R; Caputo R; Campa L; Vierucci A
    Ann Allergy Asthma Immunol; 2002 Sep; 89(3):298-303. PubMed ID: 12269651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tear cytokine levels in vernal keratoconjunctivitis: the effect of topical 0.05% cyclosporine a therapy.
    Oray M; Toker E
    Cornea; 2013 Aug; 32(8):1149-54. PubMed ID: 23676782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Satisfaction of Cyclosporine 0.1% in Patients with Vernal Keratoconjunctivitis.
    Salami E; Righetti G; Cavarzeran F; Leonardi A
    Ocul Immunol Inflamm; 2023 Nov; 31(9):1870-1872. PubMed ID: 35914313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A prospective, observational, all-prescribed-patients study of cyclosporine 0.1% ophthalmic solution in the treatment of vernal keratoconjunctivitis].
    Takamura E; Uchio E; Ebihara N; Okamoto S; Kumagai N; Shoji J; Nakagawa Y; Namba K; Fukushima A; Fujishima H; Miyazaki D; Ohashi Y
    Nippon Ganka Gakkai Zasshi; 2011 Jun; 115(6):508-15. PubMed ID: 21735754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of CD23/CD21 and CD40/CD40 ligand in vernal keratoconjunctivitis.
    Abu El-Asrar AM; Fatani RA; Missotten L; Geboes K
    Eye (Lond); 2001 Apr; 15(Pt 2):217-24. PubMed ID: 11339595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.